Advertisement

Topics

Latest "Advanced Research Systems, Inc." News Stories

16:38 EDT 25th September 2018 | BioPortfolio

Here are the most relevant search results for "Advanced Research Systems, Inc." found in our extensive news archives from over 250 global news sources.

More Information about Advanced Research Systems, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Advanced Research Systems, Inc. for you to read. Along with our medical data and news we also list Advanced Research Systems, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Advanced Research Systems, Inc. Companies for you to search.

Showing "Advanced Research Systems" News Articles 1–25 of 35,000+

Tuesday 25th September 2018

Healogics Joins the Epic App Orchard

Healogics Inc., the nation’s largest provider of advanced wound care services, today announced they have joined the App Orchard to begin working on an integration to improve interoperability within their nationwide network of Wound Care Centers®. Currently, this integration is set to deploy in the fall of 2019. This integration will allow discr...


Alexion to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York, NY on Tuesday, October 2, 2018 at 10 a.m., EDT. An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.alexion.com. An archived versio...

Doctors Launch #BreakUpWithBacon Campaign in D.C.

Hard-hitting bus shelter advertisements near D.C. hospitals will urge patients and others to #BreakUpWithBacon to prevent colon cancer. The ads warn “Bacon and other processed meats can cause colorectal cancer,” and “Bacon can bite you back!” The bus shelter ads, scheduled to start going up the week of Sept. 24, are sponsored by the Physicians Comm...


Exelixis to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018

— Presentation to be webcast on www.exelixis.com — Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the Cantor Fitzgerald Global Healthcare Conference taking place October 1-3 in New York, NY. The Exelixis presenta...

Scientists look for new biomedical research tools in the oddest places, even in the genes of fireflies "freshly nabbed from a local meadow as they blinked their way toward reproductive fulfillment." https://buff.ly/2Ieit7R 

Scientists look for new biomedical research tools in the oddest places, even in the genes of fireflies "freshly nabbed from a local meadow as they blinked their way toward reproductive fulfillment." https://buff.ly/2Ieit7R 

Protea Biosciences Group Inc PRGB Medical Equipment Deals and Alliances Profile [Report Updated: 12072018] Prices from USD $250

SummaryProtea Biosciences Group Inc Protea is a biotechnology company that develops mass spectometry solutions. The company offers technology for the characterization, identification, and quantitation of biologicallyimportant molecules for research, pharmaceutical development, and diagnostic applications. Its products include protein sample preparation, functionalized pipette tips and plates, gel ...

Kedalion Therapeutics Broadens Leadership Team with Vice President of Engineering

Kedalion Therapeutics, Inc., a clinical-stage company focused on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream™ platform, today announced the hiring of medical device industry veteran Reynaldo Quintana as Vice President of Engineering. “We are pleased to have Reynaldo join the Kedal...

The Trump administration is going to review all fetal tissue research https://www.buzzfeednews.com/article/danvergano/hhs-fetal-tissue-review … #NBTInTheirWordspic.twitter.com/FTpDtV16co

The Trump administration is going to review all fetal tissue research https://www.buzzfeednews.com/article/danvergano/hhs-fetal-tissue-review … #NBTInTheirWords pic.twitter.com/FTpDtV16co

Freedom Innovations Expands its Hydraulic Ankle Technology to K2 Space with Kintrol Launch

Freedom Innovations has launched the Kintrol Hydraulic Ankle/Foot system, combining advanced Kinterra hydraulic ankle technology with the highest quality, aerospace-grade fiberglass to provide K2 level ambulators the comfort and control they demand. K2 ambulators are prosthetic users who are typically defined as having the ability or potential for...

Infectious Bacteria Hibernate to Evade Antibiotics

NewsResearchers have discovered a surprising tactic of pathogenic bacteria when being attacked by antibiotics: hibernation.Con

Looking Ahead to Infrared

NewsA new infrared camera narrows the gap between basic and applied research in additive manufacturing.Contributed Author: 

Advanced Animal Society Thrives Without Males

NewsTermite colonies have been found to thrive and reproduce without males.Contributed Author: 

Canada’s Economic Strategy Tables Recommendations for Health and Biosciences Applauded by BioTalent Canada

Today, BioTalent Canada congratulated Canada’s Economic Strategy Tables on its talent-based recommendations contained in its report: “The Innovation and Competitiveness Imperative” for the Health and Bioscience sector, which constitutes the largest sector of Canada’s bio-economy. The economic round table recommended the following: ...

LabRoots Releases New 2019 Media Kit, and Announces 2019 Virtual Event Schedule

LabRoots users can preview and register for all the 2019 virtual events, as well as watch all the 2018 events on demand. YORBA LINDA, Calif. (PRWEB) September 25, 2018 LabRoots, the leading provider of interactive and educational virtual events and webinars for researchers, scientists and doctors from around the world, announces their 2019 lineup of virtual events as they release their new 2019 m...

Mauna Kea Technologies SA (MKEA-FR): H1 results reflect continued focus on the US

goetzpartners securities Limited 25-Sep-2018 / 15:58 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clien...

Merck, Accenture team with Amazon to develop a research platform for early-stage drug development

The platform will be designed to help life sciences organizations improve productivity, efficiency, and innovation in early stage drug development, says Accenture executive.

The Trump administration has launched a comprehensive review of all research that involves fetal tissue, reopening an issue that has galvanized anti-abortion activists but worried scientists. https://buff.ly/2NAwzWS pic.twitter.com/Tse5VZc80A

The Trump administration has launched a comprehensive review of all research that involves fetal tissue, reopening an issue that has galvanized anti-abortion activists but worried scientists. https://buff.ly/2NAwzWS  pic.twitter.com/Tse5VZc80A

Hospital Systems, Private Equity Firms Aggressively Pursuing Medical Practices, Survey Finds

DENVER, Sept. 25, 2018 /PRNewswire/ -- Nearly seventy percent of medical practices responding to a Clinic Service Corporation national survey have been approached by private Read more...

Takeda to Present Positive Data from Alunbrig Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50% Versus Crizotinib in Advanced ALK+ NSCLC

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) today announced results from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial, demonstrating that ALUNBRIG reduced the risk of disease progression or death, known as progression-free survival (PFS), as assessed by a blinded independent review committee...

Keystone Announces Exclusive Partnership with Wamberg Genomic Advisors

Keystone Insurers Group (Keystone) announced today an exclusive partnership with Wamberg Genomic Advisors. Keystone is the first and only property/casualty agency network to provide Cancer Guardian and other genomic programs to clients through its almost 300 independent agencies. Wamberg Genomic Advisors’ Cancer Guardian program provides persona...

In Zebrafish, a Way to Find New Cancer Therapies Targeting Tumor Modulators

NewsDespite more than 30 phase II clinical trials since 1985, there is no standard chemotherapy or drug regimen for adenoid cystic carcinoma.

Imfinzi is the First Immunotherapy to Demonstrate Significant Overall Survival Benefit in Unresectable, Stage III Lung Cancer

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of IMFINZI® (durvalumab) during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Toronto, Canada. R...

Aptar Pharma plans new product release at CPhI

Drug delivery systems provider, Aptar Pharma, will be launching its new portable respiratory device at CPhI worldwide, later this year.

Nuevolution (NUEV) - Pipeline and partnerships continue to strengthen

Edison Investment Research - Pharmaceutical & healthcare - Nuevolution: With the completion of the up-listing to the Nasdaq Stockholm main market and the successful gross SEK110m capital raise, Nuevolution continues to strengthen both its investor base and financial position. Amgen’s opt-in on the first programme in its multi-target collaboration and the identification of much sought-after s...

Trump administration launches review of scientific research involving fetal tissue

The Trump administration has launched a comprehensive review of all research that involves fetal tissue, reopening an issue that has galvanized anti-abortion activists but worried scientists.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks